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We report eight patients from our tertiary care 
neurologic outpatient department treated with 
anti-CD20 therapies, of which six showed nega-
tive SARS-CoV2-antibodies [cut-off value for 
negative tests/assay: anti-nucleocapsid IgG 1.4 
Index Alinity (Abbott, Abbott Park, IL, USA); 
anti-spike protein IgG 12.0 AU/ml; Liaison 
SARS-CoV-2 S1/S2 IgG (DiaSorin, Saluggia, 
Italy)] after a symptomatic infection with positive 
COVID-19 PCR nasopharyngeal swab. The 
remaining two patients had a strong positive 
response for anti-spike protein IgG (64.6 AU/ml) 
with negative anti-nucleocapsid IgG or a weak 
positive response for anti-spike protein IgG 
(29.3 AU/ml) and positive anti-nucleocapsid IgG 
(2.9 Index), respectively.
Six of these patients were treated with ocrelizumab 
[n = 5 with relapsing remitting (RR) multiple scle-
rosis (MS), n = 1 with primary progressive (PP) 
MS]. Two patients were treated with rituximab, 
one each for neuromyelitis optica spectrum disor-
der (NMOSD) and active secondary progressive 
(aSP) MS, respectively. Mean interval between 
last anti-CD20-infusion to positive COVID-19-
PCR nasopharyngeal swab was 4.9 months (range 
3–10 months); mean interval from positive 
COVID-19-PCR nasopharyngeal swab to SARS-
CoV2-antibody testing was 3.8 months [range 1–9 
month(s)]. Six patients were female, mean age 
was 51.1 years (range 37–69 years), mean disease 
duration was 7.8 years [range 1–16 year(s)] and 
mean expanded disability status scale (EDSS) was 
3.1 (range 1.5–4.5). Four patients with COVID-
19 were managed in an ambulatory setting, 
whereas four of our patients had a COVID-19-
infection warranting hospitalisation, but none 
needed respiratory support. For further patients 
characteristics, see Table 1. All of the patients 
included in our case series signed an informed 
consent, which includes the publication of the 
medical data in an anonymised form and this work 
is in accordance with the regulations of our local 
ethical committee.
In accordance with other case reports,1,2 these data 
highlight that patients treated with anti-CD20-
therapies may lack an antibody response after 
symptomatic COVID-19. Our findings are in line 
with other case reports, but in our study we tested 
for several epitopes (anti-nucleocapsid IgG and 
anti-spike protein), whereas in previous case 
reports, only single epitopes were measured. 
Usually, a detectable anti-spike and anti-nucle-
ocapsid IgG antibody response to SARS-CoV2 is 
present within few days after symptom onset.3  
The initial antiviral responses are driven mainly 
by T-cells, in particular CD8+ cytotoxic 
T-lymphocytes, and natural killer cells and less by 
B-cells, which may explain why patients on anti-
CD20 therapies cope relatively well with viral 
infections. So far, it is uncertain to what extent 
COVID-19 results in a long-lasting immunity, but 
it is generally accepted that neutralising antibodies 
play a crucial role in protection against coronavi-
ruses.4 Therefore, the finding of a lacking antibody 
response after a symptomatic COVID-19 in 
patients treated with anti-CD20-therapies may 
imply an increased risk for re-infection. In addi-
tion, anti-CD20-therapies may lead to an absent 
antibody response to SARS-CoV2-vaccines, as has 
been predicted by Baker et al.5 In our opinion, this 
should prompt closer surveillance including 
 monitoring of the immune response in patients 
treated with anti-CD20-therapies after both infec-
tion and vaccination, in order to clarify whether 
these individuals remain at risk for SARS-CoV-2 
infection. If vaccination or infection fails to protect 
a high proportion of patients on anti-CD20 ther-
apy, the safekeeping of these vulnerable individuals 
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will depend on herd immunity and individual pro-
tective measures such as physical distancing and 
following hygiene rules.
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